Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 84 of 84 results for neck pain

  1. Vismodegib for treating basal cell carcinoma (TA489)

    Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

  2. The OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic joint revision (MIB13)

    NICE has developed a Medtech Innovation Briefing (MIB) on the OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic

  3. Galcanezumab for preventing migraine (TA659)

    Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.

  4. Erenumab for preventing migraine (TA682)

    Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.

  5. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.

  6. The SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional changes in people with or at risk of developing glaucoma (MIB14)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional

  7. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

  8. NICE has made six times more lung cancer treatment recomendations over the past ten years than in the previous decade

    We have also recommended osimertinib for routine use on the NHS today.

  9. 170,000 people in England to have further treatment choice for preventing migraine attacks

    In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.